ARS Pharmaceuticals (SPRY) Short term Debt (2020 - 2021)
ARS Pharmaceuticals (SPRY) reported Short term Debt of $495000.0 for Q1 2021, down 41.35% sequentially from $844000.0 in Q4 2020.
ARS Pharmaceuticals (SPRY) Short term Debt (2020 - 2021) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 2 years of Short term Debt data on file, last reported at $495000.0 in Q1 2021.
- For the quarter ending Q1 2021, Short term Debt changed N/A year-over-year to $495000.0; the trailing twelve-month figure through Mar 2021 stood at $495000.0 (changed N/A YoY), and the FY2020 full-year result was $844000.0, changed N/A from the prior year.
- Short term Debt declined to $495000.0 in Q1 2021, from $844000.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $844000.0 in Q4 2020 to a low of $495000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 495,000.00 |
| Dec 31, 2020 | 844,000.00 |